Proteostasis Therapeutics, Inc. Company Profile
Proteostasis Therapeutics (PTI) is developing novel disease-modifying therapeutics that target the cellular pathways regulating protein folding, trafficking, and clearance. The Proteostasis Network (PN) is comprised of these interconnected cellular pathways and can become imbalanced by the cumulative effects of aging, disease, genetics and environmental factors. The Company is focused on improving outcomes for patients with neurodegenerative and orphan diseases with lead programs in cystic fibrosis and Parkinsonâs disease. For more information, please visit www.proteostasis.com.
News Articles
Proteostasis Nabs Partnership, $20M Investment, from Elan To Pursue Neurology Drugs
Cambridge, MA-based Proteostasis Therapeutics has found a big new benefactor to support its R&D against neurological diseases. Proteostasis said today it has formed a strategic alliance with Irela...
Diversity in the origins of proteostasis networks — a driver for protein function in evolution
All three domains of life – Bacteria, Archaea and Eukarya – have a proteostasis network that modulates protein folding in response to changes in the environment and to genetic variation. This prot...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2013 - Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurod...
Proteostasis Adds Targets, Drugs From Harvard
Proteostasis Therapeutics, the Cambridge, MA-based company seeking to keep proteins in balance to fight neurodegenerative diseases, said today it has obtained two exclusive technology licenses from Ha...
Proteostasis Therapeutics to Present Data at Two Upcoming Scientific Meetings
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan disea...
Proteostasis, Scripps Research Institute deal
Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan disea...
Drugs and Medications
None
PubMed Articles
Roles of extracellular chaperones in amyloidosis.
Extracellular protein misfolding and aggregation underlie many of the most serious amyloidoses including Alzheimer's disease, spongiform encephalopathies and type II diabetes. Despite this, protein ho...
The case for therapeutic proteostasis modulators.
A functional ubiquitin proteasome pathway (UPP) is vital for all eukaryotic cellular systems and therefore any alteration in this critical component of proteostasis machinery has potential pathologica...
Diversity in the origins of proteostasis networks - a driver for protein function in evolution.
Although the sequence of a protein largely determines its function, proteins can adopt different folding states in response to changes in the environment, some of which may be deleterious to the organ...
Protein homeostasis and aging in neurodegeneration.
Genetic and environmental factors responsible for numerous neurodegenerative diseases vary between disorders, yet age remains a universal risk factor. Age-associated decline in protein homeostasis, or...
The role of Yca1 in proteostasis. Yca1 regulates the composition of the insoluble proteome.
Proteostasis, the process of balancing protein production with protein degradation is vital to normal cell function. Defects within the mechanisms that control proteostasis lead to increased content o...
Clinical Trials
None
Companies
Proteostasis Therapeutics is discovering âProteostasis Regulatorsâ (PRs), small molecule drugs that restore proper protein function to treat neurodegenerative, metabolic...
Proteostasis Therapeutics and Elan Corporation
Proteostasis Therapeutics is developing âProteostasis Regulatorsâ (PRs), small molecule drugs that restore proper protein function or remove misfolded and aggregated pro...
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics (PTI) is developing novel disease-modifying therapeutics that target the cellular pathways regulating protein folding, trafficking, and clearance. The Pr...
More Information about "Proteostasis Therapeutics, Inc." on BioPortfolio
We have published hundreds of Proteostasis Therapeutics, Inc. news stories on BioPortfolio along with dozens of Proteostasis Therapeutics, Inc. Clinical Trials and PubMed Articles about Proteostasis Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Proteostasis Therapeutics, Inc. Companies in our database. You can also find out about relevant Proteostasis Therapeutics, Inc. Drugs and Medications on this site too.
